SPYRE THERAPEUTICS, INC. (SYRE) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $16.00K; Additional Paid in Capital, Common StockUSD $2.19B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-2.40M; Retained Earnings (Accumulated Deficit)USD $-1.23B.
- 2026-03-31: Common Stock, Value, IssuedUSD $15.00K; Additional Paid in Capital, Common StockUSD $1.71B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-767.00K; Retained Earnings (Accumulated Deficit)USD $-1.20B.
- 2025-12-31: Common Stock, Value, IssuedUSD $15.00K; Additional Paid in Capital, Common StockUSD $1.69B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $869.00K; Retained Earnings (Accumulated Deficit)USD $-1.13B.
- 2025-09-30: Common Stock, Value, IssuedUSD $13.00K; Additional Paid in Capital, Common StockUSD $1.36B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $791.00K; Retained Earnings (Accumulated Deficit)USD $-1.07B.
SPYRE THERAPEUTICS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD | Preferred Stock, Value, Issued USD | Additional Paid in Capital USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Partners' Capital Account, Distributions USD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $16.00K | $2.19B | $-2.40M | $-1.23B | $1.10B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $15.00K | $1.71B | $-767.00K | $-1.20B | $670.81M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $15.00K | $1.69B | $869.00K | $-1.13B | $715.24M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $13.00K | $1.36B | $791.00K | $-1.07B | $455.10M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $13.00K | $1.35B | $454.00K | $-1.05B | $455.77M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $13.00K | $1.34B | $682.00K | $-1.02B | $482.61M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $13.00K | $1.33B | $180.00K | $-972.43M | $517.80M | 12 month · $14.46M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $12.00K | $1.09B | $1.46M | $-916.14M | $327.39M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $12.00K | $1.07B | $-553.00K | $-847.11M | $374.38M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $10.00K | $775.97M | $-363.00K | $-808.27M | $152.27M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $10.00K | $763.19M | $302.00K | $-764.41M | $184.02M | 12 month · $11.47M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $7.00K | $455.96M | $-132.00K | $-701.23M | $-245.40M | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2023-06-30 | $6.00K | $453.74M | $11.00K | $-661.13M | $-207.37M | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2023-03-31 | $6.00K | $477.70M | $-6.00K | $-444.05M | $33.65M | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2022-12-31 | $6.00K | $475.97M | $-48.00K | $-425.62M | $50.30M | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2022-09-30 | $6.00K | $474.54M | $-184.00K | $-406.80M | $67.56M | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2022-06-30 | $6.00K | $472.94M | $-220.00K | $-388.57M | $84.16M | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2022-03-31 | $5.00K | $428.05M | $-153.00K | $-366.25M | $61.66M | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2021-12-31 | $5.00K | $425.76M | $-20.00K | $-341.81M | $83.94M | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2021-09-30 | $5.00K | $423.44M | $2.00K | $-321.36M | $102.08M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $5.00K | $420.06M | $11.00K | $-301.06M | $119.02M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $5.00K | $417.95M | $25.00K | $-294.23M | $123.75M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $5.00K | $415.82M | $11.00K | $-276.01M | $139.83M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $5.00K | $389.54M | $20.00K | $-253.29M | $136.27M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $5.00K | $387.48M | $39.00K | $-235.26M | $152.26M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-04-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1 month · $800.00K | (m) | (m) |
| 2020-03-31 | $3.00K | $256.78M | $-134.00K | $-213.84M | $42.80M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $3.00K | $255.14M | $51.00K | $-195.12M | $60.08M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $3.00K | $253.33M | $78.00K | $-173.62M | $79.80M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $3.00K | $251.59M | $67.00K | $-152.05M | $99.61M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $3.00K | (m) | $13.00K | $-134.03M | $116.29M | (m) | (m) | $250.30M | (m) | (m) | (m) |
| 2018-12-31 | $2.00K | $184.31M | $-27.00K | $-116.86M | $67.43M | (m) | (m) | $184.31M | (m) | (m) | (m) |
| 2018-09-30 | $2.00K | (m) | $-33.00K | $-101.96M | $63.68M | (m) | (m) | $165.68M | (m) | (m) | (m) |
| 2018-06-30 | $2.00K | (m) | $-56.00K | $-90.05M | $73.45M | (m) | (m) | $163.55M | (m) | (m) | (m) |
| 2018-03-31 | $2.00K | (m) | $-98.00K | $-80.63M | $43.92M | (m) | (m) | $124.65M | (m) | (m) | (m) |
| 2017-12-31 | $2.00K | (m) | $-102.00K | $-72.51M | $50.34M | (m) | (m) | $122.95M | (m) | 12 month · $2.49M | (m) |
| 2017-09-30 | $2.00K | (m) | $-32.00K | $-66.03M | $55.51M | (m) | (m) | $121.57M | (m) | (m) | (m) |
| 2017-06-30 | $2.00K | (m) | $-29.00K | $-58.16M | $62.60M | (m) | (m) | $120.79M | (m) | (m) | (m) |
| 2017-03-31 | $1.00K | (m) | $-37.00K | $-51.52M | $57.18M | (m) | (m) | $108.74M | (m) | (m) | (m) |
| 2016-12-31 | $1.00K | (m) | $-4.00K | $-45.28M | $62.97M | (m) | (m) | $108.25M | (m) | 12 month · $1.22M | (m) |
| 2016-09-30 | $1.00K | (m) | $3.00K | $-39.79M | $68.20M | (m) | (m) | $107.99M | (m) | (m) | (m) |
| 2016-06-30 | $1.00K | (m) | $1.00K | $-33.56M | $73.92M | (m) | (m) | $107.48M | (m) | (m) | (m) |
| 2016-03-31 | $0.00 | (m) | $3.00K | $-28.13M | $-26.61M | (m) | (m) | $1.51M | (m) | (m) | (m) |
| 2015-12-31 | $0.00 | (m) | $-1.00K | $-23.58M | $-22.21M | (m) | (m) | $1.37M | (m) | 12 month · $747.00K | (m) |
| 2015-03-10 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 |
| 2014-12-31 | (m) | (m) | (m) | (m) | $-11.47M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | $-1.27M | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |